General Information


We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.

Employees: 44
Founded: 2015
Contact Information
Address 9000 Virginia Manor Road, Suite 200, Beltsville, MD 20705, US
Phone Number (240) 399-4900
Web Address
View Prospectus: NextCure
Financial Information
Market Cap $329.0mil
Revenues $0 mil (last 12 months)
Net Income $-22.8 mil (last 12 months)
IPO Profile
Symbol NXTC
Exchange NASDAQ
Shares (millions): 5.0
Price range $15.00 - $15.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Morgan Stanley/ BofA Securities/ Piper Jaffray
CO-Managers -
Expected To Trade: 5/9/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change